4 – Alzheimers

An assessment has been developed which reliably predicts future performance in cognition and activities of daily living for patients with Alzheimer’s disease. Researchers writing in BioMed Central’s open-access journal Alzheimer’s Research & Therapy followed 597 patients over 15 years to identify factors associated with slow, intermediate and rapid progression.

Go here ... continue reading

Although there were promising results in a phase 2 trial, patients with mild Alzheimer disease who received the drug tarenflurbil as part of a phase 3 trial did not have better outcomes on measures of cognitive decline or loss of activities of daily living compared to patients who received placebo, ... continue reading